Ustekinumab Therapy in Inflammatory Bowel Disease: Outcomes from Routine Clinical Practice

Sanaa Berrag; Fouad Nejjari; Tarik Adioui; Mouna Tamzaourte

doi:10.63363/aijfr.2026.v07i02.3347

Ustekinumab Therapy in Inflammatory Bowel Disease: Outcomes from Routine Clinical Practice

Author(s)	Prof. Sanaa Berrag, Prof. Fouad Nejjari, Prof. Tarik Adioui, Prof. Mouna Tamzaourte
Country	Morocco
Abstract	Background: Ustekinumab has emerged as an effective therapeutic option for patients with Crohn’s disease, including those with prior exposure to other biologic agents. However, data from routine clinical practice remain essential to better characterize its effectiveness and safety in heterogeneous patient populations. Methods: We conducted a retrospective observational study including patients with Crohn’s disease treated with ustekinumab. Patients previously exposed to another biologic agent within three months before ustekinumab initiation were excluded to limit potential confounding. Clinical, biological, and treatment-related data were collected at baseline and during follow-up. Clinical response, remission rates, and safety outcomes were assessed according to predefined criteria. Results: Thirty-five patients with inflammatory bowel disease were included, including 26 with Crohn’s disease (74.3%) and 9 with ulcerative colitis (25.7%); mean age at inclusion was 44.2 years, with a male predominance (62.9%). Ustekinumab was mainly initiated after anti-TNF failure or intolerance (94.3%). After 6–24 months of follow-up, 71.4% of patients achieved a marked clinical response, while 20.0% required dose interval shortening to every 6 weeks, and 8.6% discontinued treatment due to lack of efficacy. A significant biological response was observed, with a >50% reduction in CRP and fecal calprotectin in the majority of patients by week 13. Endoscopic improvement was documented in most patients, and no treatment-related adverse events were reported. Conclusion: In this cohort, ustekinumab demonstrated sustained effectiveness and a favorable safety profile in patients with Crohn’s disease, including those with prior biologic exposure. These findings support its use as a valuable therapeutic option in routine clinical practice and are consistent with previously published observational and clinical trial data.
Keywords	Ustekinumab; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; Anti-TNF failure; Treatment outcomes
Field	Medical / Pharmacy
Published In	Volume 7, Issue 2, March-April 2026
Published On	2026-03-02
DOI	https://doi.org/10.63363/aijfr.2026.v07i02.3347

View / Download PDF File

E-ISSN 3048-7641

doi

CrossRef DOI is assigned to each research paper published in our journal.

AIJFR DOI prefix is
10.63363/aijfr

Downloads

Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 7 Isu 1 Cover Page Vol 6 Isu 6 Cover Page Vol 6 Isu 5

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA

About AIJFR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9898-79-39-59	editor@aijfr.com

Advanced International Journal for Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Ustekinumab Therapy in Inflammatory Bowel Disease: Outcomes from Routine Clinical Practice

Share this